Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa study of GSK2618960 in primary Sjögren's syndrome
2016-004258-14Phase 2Terminated
- Sponsor
- GSK
- Start
- Dec 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2 trial of GSK2618960 in primary Sjögren's syndrome (2 arms), sponsored by GSK. Primary endpoints: Adverse events, Clinical laboratory values and 2 more. Started Dec 2016; status: terminated.
02
Drugs
GSK2618960
03
Conditions
primary Sjögren's syndrome
Beyond the preview
Go deeper on 2016-004258-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004258-14.